Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Palvella Therapeutics (PVLA – Research Report). The associated price target remains the same with $38.00.
Andrew Fein’s rating is based on the promising potential of QTORIN, a formulation containing 3.9% rapamycin, in treating microcystic lymphatic malformations (mLMs) and cutaneous venous malformations (cVMs). At the International Society for the Study of Vascular Anomalies conference, key opinion leaders (KOLs) expressed optimism about QTORIN’s efficacy, citing the strong evidence of sirolimus’s effectiveness in similar conditions. The lack of approved therapies for these challenging congenital vascular lesions highlights a significant unmet medical need, making QTORIN a potentially lucrative therapeutic option.
Furthermore, the SELVA study is well-positioned to demonstrate QTORIN’s efficacy, supported by robust data from its Phase 2 trial. If the study replicates these results, QTORIN could address a market of 20,000 to 30,000 patients in the U.S., establishing a new market in the orphan dermatology space. The localized benefit, minimal systemic exposure, and mild application site reactions of QTORIN further enhance its commercial appeal, justifying Fein’s Buy rating for Palvella Therapeutics.